AmoxENI: Amoxicillin for Enteral Nutrition Intolerance in Pediatric Intensive Care Unit

Sponsor
Sohag University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05828758
Collaborator
(none)
90
1
2
12.6
7.2

Study Details

Study Description

Brief Summary

The goal of this randomized controlled study is to investigate the efficacy of enteral amoxicillin for the treatment of children with feeding intolerance in pediatric intensive care unit.

Children with feeding intolerance will be randomized into study and comparison groups. The study group will receive amoxicillin 10 mg/kg by nasogastric tube 3 times daily 10 minutes before bolus gastric feeding for 7 days. The comparison group will receive equal volume of distilled water as a placebo.

The primary outcome will be the improvement of feeding intolerance on day 7 study timepoint.

Condition or Disease Intervention/Treatment Phase
Phase 2/Phase 3

Detailed Description

Malnutrition is a common problem in critically ill children admitted to the pediatric intensive care unit (PICU) with a reported prevalence up to 57%. This condition is associated with increased length of hospital stay, morbidity (e.g., hospital-acquired infections, weakness, and longer duration of mechanical ventilation), and mortality. Data from observational studies indicate that adequate energy intake is associated with better outcomes in the PICU.

Enteral nutrition (EN) is the preferred route to administer nutritional support for critically ill children unless contraindicated. However, EN of critically ill children is challenging, and nutritional targets are commonly not attained.

EN intolerance (a clinical manifestation of delayed gastric emptying) is one of the main factors for limited delivery of enteral feeding. Promotility agents are commonly used as a first-line treatment for patients with EN intolerance. In critically ill adults, prokinetics have been shown to improve gastric emptying and enhance tolerance to gastric feeding. Available options include metoclopramide, domperidone, and erythromycin. However, there is insufficient evidence for recommending the use of prokinetics in children with critical illness to enhance gastric emptying and EN tolerance. Furthermore, currently available prokinetics are associated with serious side effects.

Amoxicillin/clavulanate combination is one of the most commonly prescribed antibiotics for children worldwide. Besides its antibacterial properties, some studies showed that amoxicillin/clavulanate could have prokinetic effects. However, well-designed randomized controlled trials to confirm the prokinetic effects of amoxicillin/clavulanate are lacking. Additionally, no human study has investigated the prokinetic effects of amoxicillin and clavulanate individually. In a study on juvenile rats, amoxicillin alone, but not clavulanate, was shown to increase the amplitude of spontaneous duodenal contractions. The use of amoxicillin alone rather than amoxicillin/clavulanate could have the advantages of avoiding the side effects of clavulanate, lowering the cost, and decreasing the risk of antibiotic resistance.

The goal of this randomized controlled study is to investigate the efficacy of enteral amoxicillin for the treatment of children with EN intolerance in PICU.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Two groups of children with enteral feeding intolerance: Study group: will receive amoxicillin 10 mg/kg (50 mg/ml concentration) by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days. The nasogastric tube will be flushed by 5 ml distilled water after each dose. Control group: will receive equal volume of distilled water (0.2 ml/kg + 5 ml) as a placebo.Two groups of children with enteral feeding intolerance:Study group: will receive amoxicillin 10 mg/kg (50 mg/ml concentration) by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days. The nasogastric tube will be flushed by 5 ml distilled water after each dose. Control group: will receive equal volume of distilled water (0.2 ml/kg + 5 ml) as a placebo.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Enrolled children will be equally randomized into study and control group using computer generated numbers, which will be sealed into sequentially numbered opaque envelopes by a person not belonging to the research team. For each enrolled participant, the envelope in order will be opened, and the assigned study drug will be used. A pharmacist will fill the active and placebo preparations in similar containers with sealed code for identification. Participants' families, treating clinicians, and investigators will be unaware of group assignment and drug/placebo therapy.
Primary Purpose:
Treatment
Official Title:
Efficacy of Amoxicillin for Treatment of Enteral Nutrition Intolerance in Pediatric Intensive Care Unit
Actual Study Start Date :
Apr 24, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
May 10, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Study group

Children receiving amoxicillin

Drug: Amoxicillin
Amoxicillin 10 mg/kg (50 mg/ml concentration) by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.

Placebo Comparator: Comparison group

Children receiving placebo

Other: Placebo
Distilled water 0.2 ml/kg by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.

Outcome Measures

Primary Outcome Measures

  1. Feeding tolerance on day 7 [7 days]

    Proportion of participants achieving feeding tolerance (enteral intake ≥ two-thirds of the prescribed daily target in the absence of gastrointestinal symptoms, including large gastric residual volume (≥ 50% of enteral feeding in the last 4 hours), vomiting (≥ 2 times gastric content in 24 hours period), diarrhea (≥ 4 times loose stool with negative fluid balance in 24 hours period), abdominal distention (≥ 2 cm increase in abdominal girth), abdominal pain, melena, or hematochezia) on day 7 study timepoint

Secondary Outcome Measures

  1. Enteral intake ≥ two-thirds of the prescribed daily target on day 7 [7 days]

    Proportion of participants achieving enteral intake ≥ two-thirds of the prescribed daily target on day 7 study timepoint

  2. Change in achieved percentage of prescribed enteral feeding on day 7 study compared with baseline [7 days]

    Change in achieved percentage of prescribed enteral feeding on day 7 study timepoint compared with baseline

  3. Large gastric residual volume on day 7 [7 days]

    Proportion of participants with large gastric residual volume (≥ 50% of enteral feeding in the last 4 hours) on day 7 study timepoint

  4. Vomiting on day 7 [7 days]

    Proportion of participants with vomiting (≥ 2 times gastric content in 24 hours period) on day 7 study timepoint

  5. Diarrhea [7 days]

    Proportion of participants with diarrhea (≥ 4 times loose stool with negative fluid balance in 24 hours period)

  6. Abdominal distention [7 days]

    Proportion of participants with abdominal distention (≥ 2 cm increase in abdominal girth)

  7. Melena/hematochezia [7 days]

    Proportion of participants with melena/hematochezia

  8. Skin rash [7 days]

    Proportion of participants with skin rash

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 12 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ranges from 1 month to 12 years.

  • Nasogastric tube feeding

  • Enteral nutrition intolerance after 7 days of admission to the PICU.

Exclusion Criteria:
  • Failure to obtain informed consent.

  • Allergy or contraindication to amoxicillin or other beta-lactam antibiotics.

  • Current or recent (within 7 days) treatment with amoxicillin.

  • Ongoing ketogenic diet.

  • Clinical contraindications to advance EN feeds (e.g., bowel obstruction/tight stenosis, severe diarrhea/malabsorption, gut ischemia, severe hypoxemia/acidosis, intractable upper gastrointestinal bleeding, abdominal compartment syndrome, high-output fistula).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Pediatric Intensive Care Unit - Sohag University Hospital Sohag Egypt 82524

Sponsors and Collaborators

  • Sohag University

Investigators

  • Study Chair: Safaa H Ali, MD, PhD, Sohag University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Abanob Amgad Francis, Pediatric Resident, Sohag University
ClinicalTrials.gov Identifier:
NCT05828758
Other Study ID Numbers:
  • Soh-Med-23-04-16MS
First Posted:
Apr 25, 2023
Last Update Posted:
Apr 26, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Abanob Amgad Francis, Pediatric Resident, Sohag University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 26, 2023